Stomach cancer

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

Debbie's Dream Foundation: Curing Stomach Cancer Announce Groundbreaking Research Fellowship Grant for Gastric Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Education, Patient, Biomarker, Research, Helicobacter pylori, AACR, DRS, DDF, Stomach, MSK, Gastrointestinal cancer, Health, Stomach cancer, Pharmaceutical industry

FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research. Through the visionary efforts and support of DDF, a research fellowship grant has been established at MSK under the guidance of Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology Service at MSK. The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers. The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.

Key Points: 
  • FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research.
  • The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers.
  • The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.
  • Through the 'Debbie's Dream Foundation Gastric Cancer Investigator fellowship, we aim to make impactful strides in biomarker development, laboratory research, and translational studies in gastroesophageal cancer."

AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA

Retrieved on: 
Tuesday, February 20, 2024
University, Start-Up, Education, Technology, Professional Services, Health, Oncology, Medical Devices, Software, Artificial Intelligence, Hospitals, Incidence, Stomach cancer, Multimedia, Physician, NUH, Nature, AIM, Communication, National University Hospital, Stomach, HSA, Extrapyramidal system, Disease, Mortality, Cancer, Medical device

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review and device registration for an AI-based endoscopic diagnostic support device that operates within the stomach (brand name: Endoscopic image diagnosis support software - gastroAI-model G).
  • The regulatory review and device registration was conducted by Singapore’s Health Sciences Authority (hereinafter HSA) on February 19, 2024.
  • The endoscopic AI (hereinafter gastric cancer differentiation AI) differentiates gastric lesions and judges them as either neoplastic or non-neoplastic in nature.
  • In countries with a high incidence of gastric cancer like Japan and South Korea, endoscopic gastric cancer screening is routinely performed nationwide.

Debbie's Dream Foundation: Curing Stomach Cancer Hosts a Historic 12th Annual Stomach Cancer Capitol Hill Advocacy Day in 2024

Retrieved on: 
Tuesday, March 5, 2024
Stomach cancer, Bangladesh Technical Education Board, Caregiver, Origin, Jazz Pharmaceuticals, News, Federation, Fiscal year, National Cancer Institute, DDF, Merck & Co., Patient, Congress, FY, Research, Pharmaceutical industry

WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC. On the morning of February 6, just as the world learned of country music legend Toby Keith's passing from stomach cancer, nearly 150 advocates demonstrated resilience and determination on Capitol Hill, attending 221 scheduled meetings with lawmakers. The advocates passionately conveyed critical asks, urging Congress to pass the Fiscal Year (FY) 2024 spending bills to prevent disruptions in essential research funding, keep stomach cancer on the Peer Reviewed Cancer Research Program (PRCRP) list for FY 2025, and increase FY 2025 funding to the National Institutes of Health and National Cancer Institute.

Key Points: 
  • WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC.
  • Their unwavering support in Congress has significantly raised stomach cancer awareness and has led to increased federal research dollars for stomach cancer.
  • Over the years, DDF's advocacy efforts have resulted in $34.4 million dedicated to stomach cancer research through the PRCRP to date.
  • DDF expresses heartfelt gratitude to all advocates, sponsors, and supporters who contributed to the success of the 12th Annual Stomach Cancer Capitol Hill Advocacy Day.

Michael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer Research

Retrieved on: 
Wednesday, February 21, 2024
Stomach cancer, Neoplasm, De Gregorio, Doctor of Philosophy, MD, Immunotherapy, Esophageal cancer, Grant, Cancer, Mitochondrion, Associate, Patient, Protein, Baylor College of Medicine, Research, Mouse, Baylor University, Pharmaceutical industry

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Normally, the tumor cell 'energy center', called the mitochondria, protect the tumor cell from treatment with either chemotherapy or immunotherapy.
  • "The support of the DeGregorio Family Foundation is critical to the success of our research; we very much appreciate it," said Dr. Ripley.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $8 million to fund innovative research to cure gastric and esophageal cancers.

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on: 
Wednesday, February 7, 2024
Antigen, Massachusetts General Hospital, Immunotherapy, Research, GEA, Stomach cancer, Patient, Safety, Bone marrow, Dana–Farber Cancer Institute, DRS, Cancer, Doctor of Philosophy, De Gregorio, GEMINI, Pharmaceutical industry

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points: 
  • They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
  • One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
  • "We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Retrieved on: 
Tuesday, January 30, 2024
PD-L1, FOLFOX, Immune system, Division, Clinical trial, RECIST, Patient, Stomach, Therapy, ICIS, Pembrolizumab, Brown University, Nivolumab, Associate, Stomach cancer, Mink, Cancer, Clinical research, Malignancy

“Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors.

Key Points: 
  • “Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors.
  • The activity, tolerability, and ease of off-the-shelf administration of iNKT-based cell therapies position them as an attractive approach for overcoming cancer resistance.”
    Gastric cancer, the fifth most common malignancy globally, is incurable with only 12% responsive to ICIs1,2.
  • This phase study (NCT05108623) was designed to evaluate agenT-797, an unmodified iNKT cell therapy, in solid tumors refractory to ICIs.
  • Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer.

Group Launches National Campaign to Help Stomach Cancer Patients Receive the Right Treatment

Retrieved on: 
Sunday, February 4, 2024
FAQ, Biomarker, Life, HER2, National Cancer Institute, Heart, Stomach cancer, Caregiver, Patient, Oncology, Diagnosis, The Test, Medicine, World Cancer Day, Medical imaging

DALLAS, Feb. 4, 2024 /PRNewswire/ -- A national education and awareness campaign called Test Your Biomarkers is launching today – World Cancer Day – to educate patients and caregivers about the importance of biomarker testing in treating stomach cancer so patients will advocate for themselves and speak to their doctors about biomarker testing.

Key Points: 
  • "The key, however, is ensuring that patients get biomarker testing so they can be paired with a treatment specific to their cancer's unique information."
  • Seven years later, Javier is a stomach cancer survivor because he received the right treatment based on his cancer's specific biomarkers.
  • Yet, many providers are unaware of the advancements in precision medicine and the importance of biomarker testing in treating stomach cancer.
  • Test Your Biomarkers is working to improve stomach cancer outcomes by educating patients and helping them advocate for themselves and biomarker testing with their doctors.

Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery

Retrieved on: 
Thursday, February 1, 2024
Immune system, Research, Stomach cancer, Patient, Safety, Diagnosis, Bone marrow, Incidence, Disease, Harvard Medical School, B cell, Vaccination, Stomach, Neoplasm, Cancer, De Gregorio, GEMINI, Vaccine

Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.

Key Points: 
  • Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.
  • Avigan and his team hypothesize that a cancer vaccine targeting gastric cancer can help to train the immune system to eradicate tumor cells throughout the body and prevent disease relapse after surgery.
  • In the present study, they will examine whether designing this type of vaccine against gastric cancer will be effective in generating an immune response directed against gastric cancer cells.
  • They will use a novel approach to generating the vaccine to culture cancer cells outside the body as a part of vaccine production.

Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer

Retrieved on: 
Tuesday, January 30, 2024
Dana–Farber Cancer Institute, Patient, Stomach cancer, GEMINI, Research, Knowledge, Cancer, Immunotherapy, De Gregorio, Drug development, Doctor of Philosophy, Therapy, Pharmaceutical industry

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.
  • This approach allows the expansion of the scope of targeted therapies beyond conventionally druggable targets such as kinases and holds tremendous promise for new therapies.
  • Patients continue to face poor prognoses following gastric and esophageal cancer diagnoses due to their chemo-resistant behavior and ability to metastasize.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.